RECURSION PHARMACEUTICALS, INC.

RXRXReported to SECin USCIK 0001601830Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 10. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 10
Form 4 lines at RECURSION PHARMACEUTICALS, INC., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Taylor Ben RChief Financial OfficerAdministrative$18,4005,396 sharesSep 16, 2026Taylor Ben RChief Financial Officer$18,400Admin · Sep 16Administrative5,396Sep 16, 2026
Khan NajatCEO and PresidentOpen-market sell$78,82222,408 sharesSep 10, 2026Khan NajatCEO and President$78,822Sell · Sep 10Open-market sell22,408Sep 10, 2026
Borgeson Blake—Open-market sell$100,20030,000 sharesSep 2, 2026Borgeson Blake$100,200Sell · Sep 2Open-market sell30,000Sep 2, 2026
Khan NajatCEO and PresidentAdministrative$254,37480,498 sharesAug 18, 2026Khan NajatCEO and President$254,374Admin · Aug 18Administrative80,498Aug 18, 2026
Hallett DavidChief Scientific OfficerAdministrative$84,23626,657 sharesAug 18, 2026Hallett DavidChief Scientific Officer$84,236Admin · Aug 18Administrative26,657Aug 18, 2026